Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables - Net (2019 - 2025)

Historic Receivables - Net for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $106.4 million.

  • Catalyst Pharmaceuticals' Receivables - Net rose 8262.62% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 8262.62%. This contributed to the annual value of $65.5 million for FY2024, which is 2235.3% up from last year.
  • Catalyst Pharmaceuticals' Receivables - Net amounted to $106.4 million in Q3 2025, which was up 8262.62% from $65.9 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Receivables - Net peaked at $106.4 million during Q3 2025, and registered a low of $5.6 million during Q1 2021.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Receivables - Net value was $42.8 million (recorded in 2023), while the average stood at $38.3 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Receivables - Net crashed by 1904.39% in 2021 and then surged by 41460.85% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Receivables - Net (Quarter) stood at $6.6 million in 2021, then surged by 57.71% to $10.4 million in 2022, then soared by 412.64% to $53.5 million in 2023, then grew by 22.35% to $65.5 million in 2024, then surged by 62.52% to $106.4 million in 2025.
  • Its last three reported values are $106.4 million in Q3 2025, $65.9 million for Q2 2025, and $71.3 million during Q1 2025.